What is the NeXT Dx test?

A personalized treatment approach

No two tumors are alike. The NeXT Dx™ test gives results specific to each patient’s cancer, maximizing the clinician’s chances of finding an FDA-approved therapy or clinical trial. And by covering the entire exome, the NeXT Dx test reports on modern, advanced biomarkers that may be missed by smaller panels.

Clinical Portal

What makes it different?

The NeXT Dx test goes above and beyond other comprehensive genomic profiling tests:

Personalized Tumor/Normal Approach

More accurately identifies somatic alterations with fewer false positives than a tumor-only approach, while also identifying incidental, cancer-related germline variants.*

Future-Driven Platform™

Comprehensive whole exome and whole transcriptome validation allows for faster integration of new biomarkers as the field of oncology evolves.

Optimized, RNA-Based Fusion Detection

Novel and known fusion detection using RNA sequencing with deeper coverage compared to other transcriptome tests.

Market Leading Technology

Proprietary ACE (Accuracy and Content Enhanced) Technology® delivers augmented coverage of ~20,000 genes including difficult-to-sequence regions missed by conventional methods.

*Requires confirmatory germline testing.

How does it work

Follow this simple, five-step process

Contact Information

Client Services

+1 (855) 373-7978 or [email protected]
6:00 a.m. – 5:00 p.m. PST, weekdays.

Patient Billing Services

+1 (855) 373-7974 or [email protected]
6:30 a.m. – 4:00 p.m. PST, weekdays.

Important Safety Information

NeXT Dx is a next-generation sequencing (NGS) based laboratory developed test (LDT) for cancer patients with solid tumors. NeXT Dx analyzes the whole exome to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), and gene fusions in select cancer-related genes as well as MSI and exome-wide “true” TMB. Alterations detected by NeXT Dx are reported with associated therapeutics or clinical trial based on established clinical literature and available clinical trial enrollment criteria. Genomic findings are not prescriptive or conclusive for labeled use of any specific therapeutic product. Tests may result in no reportable alterations and/or no associated therapeutics or clinical trials. A negative result does not rule out the presence of an alteration. NeXT Dx is performed in the CLIA/CAP accredited Personalis Clinical Laboratory. NeXT Dx was developed and performance characteristics determined by the Personalis Clinical Laboratory. NeXT Dx has not been cleared or approved by the United States Food and Drug Administration (FDA). The Personalis Clinical Laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.

Let’s work together
in the fight against cancer.

Contact Us